UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
AMLX holding history
Amylyx Pharmaceuticals, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
AMLX overviewAll 13F holders of AMLXFull Q2 2026 holdings
- Shares (Q2 2026)
- 271,881
- Value
- $4.88M
- % of portfolio
- <0.1%
- Quarters held
- 18
- Since Q1 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 271,881 | $4.88M | <0.1% | −52,438−16.2% | Reduced | Holders |
| Q1 2026 | 324,319 | $4.51M | <0.1% | −219,004−40.3% | Reduced | Holders |
| Q4 2025 | 543,323 | $6.56M | <0.1% | −861,148−61.3% | Reduced | Holders |
| Q3 2025 | 1,404,471 | $19.1M | <0.1% | +151,127+12.1% | Added | Holders |
| Q2 2025 | 1,253,344 | $8.03M | <0.1% | −135,083−9.7% | Reduced | Holders |
| Q1 2025 | 1,388,427 | $4.92M | <0.1% | +744,903+115.8% | Added | Holders |
| Q4 2024 | 643,524 | $2.43M | <0.1% | +414,448+180.9% | Added | Holders |
| Q3 2024 | 229,076 | $742.2K | <0.1% | +198,937+660.1% | Added | Holders |
| Q2 2024 | 30,139 | $57.3K | <0.1% | −180,434−85.7% | Reduced | Holders |
| Q1 2024 | 210,573 | $598.0K | <0.1% | +171,559+439.7% | Added | Holders |
| Q4 2023 | 39,014 | $574.3K | <0.1% | +34,403+746.1% | Added | Holders |
| Q3 2023 | 4,611 | $84.4K | <0.1% | −69,464−93.8% | Reduced | Holders |
| Q2 2023 | 74,075 | $1.60M | <0.1% | +27,522+59.1% | Added | Holders |
| Q1 2023 | 46,553 | $1.37M | <0.1% | +43,076+1,238.9% | Added | Holders |
| Q4 2022 | 3,477 | $128.5K | <0.1% | −510−12.8% | Reduced | Holders |
| Q3 2022 | 3,987 | $112.0K | <0.1% | +3,810+2,152.5% | Added | Holders |
| Q2 2022 | 177 | $3.00K | <0.1% | −3,980−95.7% | Reduced | Holders |
| Q1 2022 | 4,157 | $53.0K | <0.1% | +4,157 | New | Holders |